
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145868810.1021/acsomega.8b00520ArticleC–H Imidation of 7-Deazapurines Sabat Nazarii †‡Poštová Slavětínská Lenka ‡Klepetářová Blanka ‡Hocek Michal *†‡† Department
of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 12843 Prague-2, Czech Republic‡ Institute
of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Gilead & IOCB Research Center, Flemingovo nám. 2, 16610 Prague-6, Czech Republic* E-mail: hocek@uochb.cas.cz. Web address: http://www.uochb.cas.cz/hocekgroup/.27 04 2018 30 04 2018 3 4 4674 4678 19 03 2018 20 04 2018 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

We
developed and presented here a ferrocene-catalyzed C–H
imidation of 7-deazapurines (pyrrolo[2,3-d]pyrimidines)
with N-imidyl peroxyesters. The reactions occur regioselectively
at position 8 in 7-deazapurines, leading to a series of 8-succinimido-,
phtalimido-, or naphthalimido-7-deazapurine derivatives. Attempted
hydrazinolysis of resulting 8-imidyl-7-deazapurines led to corresponding
8-amino-7-deazapurine, which was very unstable and quickly decomposed.

document-id-old-9ao8b00520document-id-new-14ao-2018-00520kccc-price
==== Body
Introduction
Pyrrolo[2,3-d]pyrimidines (7-deazapurines)1 are carba analogues of purine bases, which exert
diversity of biological activities (for clarity and as reference to
purines, the (7-deaza)purine nomenclature will be used in Results and Discussion, but the correct IUPAC names
are given in the Experimental Section part).
Several classes of substituted 7-deazapurine bases are inhibitors
of protein kinases2 and other enzymes,3 resulting in therapeutically relevant biological
effects. Also, many types of 7-deazapurine nucleosides were reported
as anticancer agents.4,5 Therefore, several synthetic approaches
to diverse di-, tri-, or tetra-substituted 7-deazapurines were reported.6 Introduction of a substituent onto the deazapurine
scaffold can be achieved either through classical nucleophilic substitution
or cross-coupling of a halogen or through C–H activation reactions.7 In the recent years, our group and others reported
C–H borylations,8 aminations,9 and phosphonations10 which proceeded at position 8, whereas the Cu-catalyzed C–H
sulfenylations proceeded at position 7.11 On the other hand, the Ir-catalyzed C–H silylation of 6-aryl-7-deazapurines
proceeded predominantly at the aryl group.12 Therefore, we decided to study a complementary C–H imidation
of 7-deazapurine bases to investigate the regioselectivity and possible
use in the synthesis of new deazapurine derivatives for biological
activity screening.

C–H imidations have been reported
in the literature on several
arene and heterocycle substrates using diverse reagents, such as N-fluorobenzenesulfonimide under Cu13 or Ag catalysis,14 as well as N-halophtalimide derivatives,15 or N-bromosacharin16 under photoredox catalysis. The most general seems to be the use
of N-succinimidyl peroxyester (NSP)17 under ferrocene catalysis. Therefore, we decided to use
of the latter reagent for imidation of 7-deazapurines.

Results and Discussion
We selected 6-phenyl-9-benzyl-7-deazapurine 1a as
a model compound to study its C–H imidation reaction with NSP172a under ferrocene catalysis (Table 1). The uncatalyzed
reactions with 2 equiv of NSP gave only traces of the desired product 3a (entries 1 and 2). The reaction in the presence of 5 mol
% of catalyst in dichloromethane (DCM) at 50 °C gave 3a in 12% yield (entry 3). An increase of the excess of NSP 2a to 2.5 or 2.75 equiv resulted in increased yields of 28 and 32%,
respectively (entries 4 and 5). However, further increase of NSP to
3 and 5 equiv did not bring any improvement (entries 6 and 7, respectively).
Next, we decided to test the influence of ferrocene catalyst loadings,
and with a lower amount of 1 mol %, we observed a decrease of the
reaction yield to 23%, whereas with a higher amount of 20 mol %, the
yield remained the same (entries 8 and 9). We also tried alternative
catalysts, for example, a more electron-rich ferrocene, Cu(I), Mn(III),
Pd(II), or Rh2(esp)2, which all worked to a
certain extent, but none of them brought any improvement (entries
10–14). Also, all attempts to use other solvents or higher
temperature had no positive effect (entries 15–18). Finally,
by tuning the reaction concentration, we obtained a slightly better
(37%) yield of desired product 3a when performing the
reaction in more diluted solution (entry 20). In most reactions, we
also recovered ca. 30% of the unreacted starting material and the
rest was an inseparable mixture of some highly polar compounds, presumably
products of degradation. All other efforts to improve the yield by
prolongation of the reaction time or by the use of additives were
unsuccessful, and we used the best conditions (from entry 20) in further
study.

Table 1 Optimization of C–H Imidation
Reaction of 6-Ph-9-Bn-7-Deazapurine (1a) with N-Succinimidyl Peroxyester (2a)a
entry	2a, equiv	catalyst, equiv	solvent	T, °C	yield, %	
1	2.0	 	DCM	20	2	
2	2.0	 	DCM	50	5	
3	2.0	Cp2Fe (5%)	DCM	50	12	
4	2.5	Cp2Fe (5%)	DCM	50	28	
5	2.75	Cp2Fe (5%)	DCM	50	32	
6	3.0	Cp2Fe (5%)	DCM	50	32	
7	5.0	Cp2Fe (5%)	DCM	50	32	
8	2.75	Cp2Fe (1%)	DCM	50	23	
9	2.75	Cp2Fe (20%)	DCM	50	32	
10	2.75	(Ph2Cp)2Fe (5%)	DCM	50	27	
11	2.75	CuOAc (10%)	DCM	50	11	
12	2.75	Mn(OAc)3 (10%)	DCM	50	5	
13	2.75	Pd(OAc)2 (10%)	DCM	50	8	
14	2.75	Rh2(esp)2 (5%)	DCM	50	21	
15	2.75	Cp2Fe (5%)	DCE	70	27	
16	2.75	Cp2Fe (5%)	THF	50	15	
17	2.75	Cp2Fe (5%)	MeCN	80	11	
18	2.75	Cp2Fe (5%)	TFE	50	16	
19b	2.75	Cp2Fe (5%)	DCM	50	23	
20c	2.75	Cp2Fe (5%)	DCM	50	37	
21d	2.75	Cp2Fe (5%)	DCM	50	32	
a Reagents and conditions: for 0.1
mmol of 1a, 1 mL of DCM, under Ar, 5 h.

b For 0.1 mmol of 1a,
0.2 mL of DCM.

c For 0.1 mmol
of 1a,
2 mL of DCM.

d 1 equiv of
LiOtBu as an additive.

With optimized reaction conditions
in hand, our next step was to
study the scope and limitations of the method. A series of diverse
6,9-disubstituted 7-deazapurines was tested in C–H imidation
reactions (Scheme 1).

Figure 1 ORTEP18 view of 3a (CCDC
1814891) shown
with 50% probability displacement ellipsoids.
The reactions of 6-phenyl-, 6-methyl-, and 6-chloro-substituted
deazapurines 1a–c proceeded smoothly, giving the
desired products 3a–c in acceptable 30–37%
yield. Next, we tested the tolerance of other protecting groups at
position 9 of 7-deazapurine, and C–H imidation proceeded smoothly
with (2-trimethylsilyl)-ethoxymethyl)-protected deazapurine to give
imidated product 3d in acceptable 43% yield. Then, we
tried C–H imidation of deazapurine 1a with bulkier
peroxyesters 2b and 2c bearing phtalimidyl
and naphtalimidyl groups. These reactions proceeded reasonably well
to afford desired products 3e and 3f in
33–35% yields. On the other hand, the C–H imidation
of the 9-benzyl-7-deazaadenine derivative 1e did not
proceed, showing that the free amino group is not compatible with
this reaction. Also, the attempted reaction of 9-unsubstituted 6-phenyl-7-deazapurine
did not give product of imidation. We also tried other related heterocycles,
that is, 9-benzyl-6-phenylpurine 4 or -6-phenyl-9-deazapurine 5, and we did not observe any reaction. The structure of 8-imidated-7-deazapurine 3a was confirmed by X-ray crystallography (Figure 1).

Scheme 1 Preparative C−H
Imidation of 7-Deazapurines
Because the succinimide or phthalimide moieties often
serve as
the masked amino groups, we also attempted to cleave them to access
8-amino-7-deazapurines. The hydrazinolysis of 3a or 3e proceeded smoothly, but we were unable to isolate desired
8-amino product 6 in pure form because of the low stability
and fast decomposition (Scheme 2). 8-Amino-7-deazapurine 6 was brightly fluorescent,
but the fluorescence disappeared within several minutes because of
the decomposition of the compound. This observation is in accordance
with previously reported low stability of related 8-methylamino-7-deazapurines
under acidic conditions.9 Apparently, the
free amino function at position 8 of 7-deazapurines makes the molecule
very unstable. Analogous 2-aminoindoles were also reported to be prone
to protonation, tautomerization, and auto-oxidation.19

Scheme 2 Hydrazinolysis of 8-Imido-7-deazapurine Derivatives 3a, 3e
Conclusions
We explored ferrocene-catalyzed direct
C–H imidations of
7-deazapurine nucleobases with several types of imidyl peroxyesters.
The reactions proceeded with moderate yields, but regioselectively
at position 8 of 7-deazapurines to give novel 6,9-disubstituted 8-imidyl-7-deazapurine
bases. The method was applicable for 6-chloro-, 6-substituted and
9-protected deazapurines. On the other hand, the protocol was not
compatible with deazaadenine, 9-unsubstituted 7-deazapurine, 9-deazapurine,
and purine derivatives. The hydrazinolysis of 8-imidyl-7-deazapurines
gave very unstable 8-amino-7-deazapurine, which quickly decomposed.
The C–H imidation methodology complements the current toolbox
of reactions for modification of the privileged deazapurine scaffold
and could be used for the further synthesis of modified deazapurine
heterocycles for biological activity screening.

Experimental Section
General
6-Chloro-7-deazapurine, 6-chloro-9-deazapurine,
6-chloro purine, N-hydroxysuccinimide, N-hydroxyphthalimide, N-hydroxy-1,8-naphthalimide,
and tert-butyl α-bromoisobutyrate were purchased
from commercial suppliers and used without any further purification.
Compounds 1a–b, 1e, 1f, 5,8a1c,9 and 1d(8b) were prepared according to reported procedures. Peroxyesters 2a–c(17) were prepared analogously
to a reported procedure starting from N-hydroxyimides.
Dry solvents were used as received from the supplier. All reactions
were carried out under an argon atmosphere. All compounds were fully
characterized by NMR, and spectra were recorded with a 500 MHz (499.8
or 500.0 MHz for 1H and 125.7 MHz for 13C) spectrometer. 1H and 13C resonances were assigned based on H,C-HSQC
and H,C-HMBC spectra. The samples were measured in CDCl3, and chemical shifts (in ppm, δ-scale) are referenced to solvent
signal in CDCl3 [δ (1H) = 7.26 ppm, δ
(1H) = 77.0 ppm] or in [d6]DMSO
[δ (1H) = 2.50 ppm, δ (1H) = 39.43
ppm]. Coupling constants (J) are given in hertz.
High-performance flash column chromatography purifications were performed
on KP-Sil columns. High-resolution (HR) mass spectra were measured
on a LTQ Orbitrap XL spectrometer using the electrospray ionization
(ESI) or electron impact ionization technique. IR spectra were recorded
using the KBr method (wavenumbers are given in cm–1). Melting points were determined on a Kofler block and are uncorrected.
X-ray diffraction experiment of single crystals was carried out by
monochromatized Cu Kα radiation (λ = 1.54180 Å) at
180 K.

General Procedure for C–H Imidation of 7-Deazapurines
7-Deazapurine 1a–d (1.0 mmol), ferrocene (9.3
mg, 0.05 mmol), and perester 2a–c (2.75 mmol)
were placed in a vial which was purged with argon. Then, degassed
DCM (20 mL) was added, and the reaction mixture was heated to 50 °C
and stirred for 5 h. Upon cooling, saturated Na2CO3 (25 mL) was added, followed by extraction with EtOAc (2 ×
25 mL). Combined organic layers were dried over anhydrous sodium sulfate,
filtered, and evaporated under vacuum. The crude material was purified
by flash column chromatography on silica gel, eluting with hexane/EtOAc
to afford the corresponding products.

1-(7-Benzyl-4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidine-2,5-dione
(3a)
1a (285 mg, 1 mmol) and 2a (752 mg, 2.75
mmol) were used as starting compounds to give product 3a (142 mg, 37%) as brownish crystals after chromatography (50–60%
of EtOAc in hexanes) and crystallization from EtOAc/hexane. mp 176–177
°C. 1H NMR (500 MHz, CDCl3): 2.56 (vbs,
4H, CH2–C4H4O2N),
5.52 (s, 2H, CH2-Ph), 6.84 (s, 1H, H-5), 7.10 (m, 2H, H-o-Bn), 7.26–7.34 (m, 3H, H-p,m-Bn), 7.49–7.58 (m, 3H, H-m,p-Ph), 8.10 (m, 2H, H-o-Ph), 9.06 (s, 1H,
H-2). 13C NMR (125.7 MHz, CDCl3): 28.19 (CH2–C4H4O2N), 46.11 (CH2-Ph), 100.59 (CH-5); 114.43 (C-4a), 126.94 (CH-o-Bn), 127.71 (C-6), 128.10 (CH-p-Bn), 128.81 (CH-m-Ph), 128.89 (CH-o-Ph), 128.92 (CH-m-Bn), 130.29 (CH-p-Ph), 135.82 (C-i-Bn), 137.66 (C-i-Ph), 151.39 (C-7a),
152.55 (CH-2), 158.34 (C-4), 174.76 (CO–C4H4O2N). IR (KBr): 3132, 2950, 1724, 1589, 1538, 1336,
1156, 946, 728, 692. HRMS (ESI): [M + H] calcd for C23H19N4O2, 383.1502; found, 383.1501.

1-(7-Benzyl-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidine-2,5-dione (3b)
1b (243 mg, 1 mmol) and 2a (752 mg, 2.75
mmol) were used as starting compounds to give product 3b (102 mg, 30%) as yellowish crystals after chromatography (50–60%
of EtOAc in hexanes) and crystallization from EtOAc/hexane. mp 229–230
°C. 1H NMR (500 MHz, CDCl3): 2.57 (vbs,
4H, CH2–C4H4O2N),
5.46 (s, 2H, CH2-Ph), 6.64 (s, 1H, H-5), 7.06 (m, 2H, H-o-Bn), 7.27–7.34 (m, 3H, H-p,m-Bn), 8.74 (s, 1H, H-2). 13C NMR (125.7 MHz,
CDCl3): 28.21 (CH2–C4H4O2N), 46.64 (CH2-Ph), 99.66 (CH-5),
116.23 (C-4a), 126.89 (CH-o-Bn), 127.93 (C-6), 128.31
(CH-p-Bn), 129.01 (CH-m-Bn), 135.25
(C-i-Bn), 150.71 (C-7a), 151.79 (CH-2), 152.83 (C-4),
174.50 (CO–C4H4O2N). IR (KBr):
3114, 3058, 1724, 1553, 1464, 1338, 1162, 940, 701, 597. HRMS (ESI):
[M + H] calcd for C17H14N4O2Cl, 341.0799; found, 341.0799.

1-(7-Benzyl-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidine-2,5-dione
(3c)
1c (223 mg, 1 mmol) and 2a (752 mg, 2.75
mmol) were used as starting compounds to give product 3c (99 mg, 31%) as a brownish solid after chromatography (80–90%
of EtOAc in hexane). mp 190–200 °C. 1H NMR
(500 MHz, DMSO-d6): 2.70 (s, 3H, CH3), 2.81 (s, 2 × 2H, H-4′,5′), 5.29 (s,
2H, CH2-Ph), 6.77 (s, 1H, H-5), 7.11 (m, 2H, H-o-Bn), 7.19–7.28 (m, 3H, H-m,p-Bn), 8.76 (s, 1H, H-2). 13C NMR (125.7 MHz,
DMSO-d6): 21.12 (CH3-4), 28.95
(CH2-4′,5′), 45.17 (CH2-Ph), 99.24
(CH-5), 116.31 (C-4a), 127.40 (CH-o-Bn), 127.72 (CH-p-Bn), 128.32 (C-6), 128.69 (CH-m-Bn),
136.86 (C-i-Bn), 149.04 (C-7a), 151.43 (CH-2), 159.47
(C-4), 176.70 (CO-1′,3′). IR (KBr): 3138, 2926, 1727,
1589, 1462, 1359, 1162, 896, 734, 695. HRMS (ESI): [M + Na] calcd
for C18H16N4O2Na, 343.1165;
found, 343.1157.

1-(4-Methoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidine-2,5-dione
(3d)
1d (279 mg, 1 mmol) and 2a (752 mg, 2.75 mmol) were used as starting compounds to
give product 3d (172 mg, 43%) as brownish oil after chromatography
(50–60% of EtOAc in hexane). 1H NMR (500 MHz, DMSO-d6): −0.12 (s, 9H, CH3Si),
0.76 (m, 2H, OCH2CH2Si), 2.90 (s, 4H, CH2CO), 3.33 (m, 2H, OCH2CH2Si), 4.07 (s,
3H, CH3O), 5.42 (s, 2H, NCH2O), 6.58 (s, −H,
H-5), 8.53 (s, 1H, H-2). 13C NMR (125.7 MHz, DMSO-d6): −1.30 (CH3Si), 17.30 (OCH2CH2Si), 28.97 (CH2CO), 54.03 (CH3O), 65.48 (OCH2CH2Si), 70.46 (NCH2O), 98.45 (CH-5), 103.79 (C-4a), 126.27 (C-6), 151.29 (C-7a),
152.02(CH-2), 162.52 (C-4), 176.81 (CH2CO). IR (KBr): 2951,
1728, 1559, 1479, 1364, 1169, 1081, 837, 696. HRMS (ESI): [M + Na]
calcd for C17H24N4O4NaSi,
399.1459; found, 399.1460.

2-(7-Benzyl-4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)isoindoline-1,3-dione (3e)
1a (285 mg, 1 mmol) and 2b (884 mg, 2.75
mmol) were used as starting compounds to give product 3e (151 mg, 35%) as brownish crystals after chromatography (50–60%
of EtOAc in hexanes) and crystallization from EtOAc/hexane. mp 139–140
°C. 1H NMR (500 MHz, DMSO-d6): 5.47 (s, 2H, CH2Ph), 7.03 (m, 2H, o-Bn), 7.12–7.16 (m, 3H, m-Bn, p-Bn), 7.23 (s, 1H, H-5), 7.56–7.64 (m, 3H, m-Ph, p-Ph), 7.93–8.01 (m, 4H, H-4′,H-5′,H-6′,H-7′),
8.16 (m, 2H, o-Ph), 9.01 (s, 1H, H-2). 13C NMR (125.7 MHz, DMSO-d6): 45.43 (CH2Ph), 100.96 (CH-5), 113.98 (C-4a), 124.31 (CH-4′,CH-7′),
127.21 (CH-o-Bn), 127.75 (CH-p-Bn),
128.69 (CH-m-Bn), 128.98 (CH-o-Ph),
129.29 (C-6), 129.34 (CH-m-Ph), 131.02 (CH-p-Ph), 131.63 (C-3a′,C-7a′), 135.60 (CH-5′,CH-6′),
136.71 (C-i-Bn), 137.02 (C-i-Ph),
150.89 (C-7a), 152.11 (CH-2), 156.71 (C-4), 166.75 (C=O). IR
(KBr): 3120, 2944, 1723, 1574, 1512, 1328, 1101, 943, 726, 691. HRMS
(ESI): [M + H] calcd for C27H19N4O2, 431.1502; found, 431.1503.

2-(7-Benzyl-4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (3f)
1a (143 mg, 0.5 mmol)
and 2c (511 mg,
1.375 mmol) were used as starting compounds to give product 3f (79 mg, 33%) as a yellowish solid after chromatography
(50–60% of EtOAc in hexane). mp 181–182 °C. 1H NMR (500 MHz, DMSO-d6): 5.42
(s, 2H, CH2-Ph), 7.05–7.12 (m, 5H, H-o,m,p-Bn), 7.19 (s, 1H, H-5), 7.54–7.62
(m, 3H, H-m,p-Ph), 7.92 (dd, 2H, J5′,6′ = 8.3 Hz, J5′,4′ = 7.3 Hz, H-5′,8′),
8.18 (m, 2H, H-o-Ph), 8.49 (dd, 2H, J4′,5′ = 7.3 Hz, J4′,6′ = 1.3 Hz, H-4′,9′), 8.56 (dd, 2H, J6′,5′ = 8.3 Hz, J6′,4′ = 1.3 Hz, H-6′,7′), 8.98 (s, 1H, H-2). 13C NMR (125.7 MHz, DMSO-d6): 45.38 (CH2-Ph), 99.96 (CH-5), 114.10 (C-4a), 122.10 (C-3′a,9′a),
127.36 (CH-p-Bn), 127.51 (CH-5′,8′),
127.58 (CH-o-Bn), 128.32 (CH-m-Bn),
128.78 (CH-o-Ph), 128.30 (C-9′b), 129.15 (CH-m-Ph), 130.63 (CH-p-Ph), 131.45 (CH-4′,9′),
131.72 (C-6′a), 132.90 (C-6), 135.36 (CH-6′,7′),
136.75 (C-i-Bn), 137.47 (C-i-Ph),
150.79 (C-7a), 150.86 (CH-2), 156.35 (C-4), 163.80 (CO-1′,3′).
IR (KBr): 3064, 2977, 2358, 1685, 1583, 1347, 1324, 1183, 782, 698.
HRMS (ESI): [M + H] calcd for C31H21N4O2, 481.1659; found, 481.1659.

7-Benzyl-4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-6-amine (6)
3a or 3e (0.2 mmol)
was placed in a vial which was purged with argon,
followed by addition of methanol (1 mL). Then, hydrazine hydrate (50%
solution in water) (0.04 mL, 0.6 mmol) was added dropwise and stirred
for 1 h. Product 6 was detectable by thin-layer chromatography,
crude NMR, and HR mass spectrometry but was not isolated in pure form
because of a very low stability and fast decomposition. HRMS (ESI):
[M + H] calcd for C19H17N4, 301.1447;
found, 301.1447.

Supporting Information Available
The Supporting
Information is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b00520.Copies of 1H and 13C NMR spectra
and crystallographic data (PDF)

Crystallographic data of 3a (CIF)



Supplementary Material
ao8b00520_si_001.pdf

 ao8b00520_si_002.cif

 The authors
declare no competing financial interest.

Acknowledgments
This work was supported by the institutional support
of the Charles University and Czech Academy of Sciences (RVO: 61388963
and Praemium Academiae to M.H.), by the Czech Science Foundation (16-00178S
to M.H. and N.S.), by the Ministry of Education of the Czech Republic
project LO1304 (program “NPU I” to B.K.), and by Gilead
Sciences.
==== Refs
References
De
Coen L. M. ; Heugebaert T. S. A. ; García D. ; Stevens C. V. 
Synthetic Entries to and Biological Activity of Pyrrolopyrimidines . Chem. Rev. 
2016 , 116 , 80 –139 . 10.1021/acs.chemrev.5b00483 .26699634 
a Ding S. ; Wu T. Y. H. ; Brinker A. ; Peters E. C. ; Hur W. ; Gray N. S. ; Schultz P. G. 
Synthetic
Small Molecules That Control
Stem Cell Fate . Proc. Natl. Acad. Sci. U.S.A. 
2003 , 100 , 7632 –7637 . 10.1073/pnas.0732087100 .12794184  b Traxler P. ; Allegrini P. R. ; Brandt R. ; Brueggen J. ; Cozens R. ; Fabbro D. ; Grosios K. ; Lane H. A. ; McSheehy P. ; Mestan J. ; Meyer T. ; Tang C. ; Wartmann M. ; Wood J. ; Caravatti G. 
AEE788: A Dual Family Epidermal Growth
Factor receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor
Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity . Cancer Res. 
2004 , 64 , 4931 –4941 . 10.1158/0008-5472.can-03-3681 .15256466  c Jiao X. ; Kopecky D. J. ; Liu J. ; Liu J. ; Jaen J. C. ; Cardozo M. G. ; Sharma R. ; Walker N. ; Wesche H. ; Li S. ; Farrelly E. ; Xiao S.-H. ; Wang Z. ; Kayser F. 
Synthesis and Optimization of Substituted
Furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines
as ACK1 Inhibitors . Bioorg. Med. Chem. Lett. 
2012 , 22 , 6212 –6217 . 10.1016/j.bmcl.2012.08.020 .22929232  d Scott J. S. ; Degorce S. L. ; Anjum R. ; Culshaw J. ; Davies R. D. M. ; Davies N. L. ; Dillman K. S. ; Dowling J. E. ; Drew L. ; Ferguson A. D. ; Groombridge S. D. ; Halsall C. T. ; Hudson J. A. ; Lamont S. ; Lindsay N. A. ; Marden S. K. ; Mayo M. F. ; Pease J. E. ; Perkins D. R. ; Pink J. H. ; Robb G. R. ; Rosen A. ; Shen M. ; McWhirter C. ; Wu D. 
Discovery and Optimization of Pyrrolopyrimidine
Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for
the Treatment of Mutant MYD88L265PDiffuse Large B-Cell Lymphoma . J. Med. Chem. 
2017 , 60 , 10071 –10091 . 10.1021/acs.jmedchem.7b01290 .29172502  e Riggs J. R. ; Nagy M. ; Elsner J. ; Erdman P. ; Cashion D. ; Robinson D. ; Harris R. ; Huang D. ; Tehrani L. ; Deyanat-Yazdi G. ; Narla R. K. ; Peng X. ; Tran T. ; Barnes L. ; Miller T. ; Katz J. ; Tang Y. ; Chen M. ; Moghaddam M. F. ; Bahmanyar S. ; Pagarigan B. ; Delker S. ; LeBrun L. ; Chamberlain P. P. ; Calabrese A. ; Canan S. S. ; Leftheris K. ; Zhu D. ; Boylan J. F. 
The Discovery of a Dual TTK Protein Kinase/CDC2-Like
Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast
Cancer Initiated from a Phenotypic Screen . J.
Med. Chem. 
2017 , 60 , 8989 –9002 . 10.1021/acs.jmedchem.7b01223 .28991472  f Vazquez M. L. ; Kaila N. ; Strohbach J. W. ; Trzupek J. D. ; Brown M. F. ; Flanagan M. E. ; Mitton-Fry M. J. ; Johnson T. A. ; TenBrink R. E. ; Arnold E. P. ; Basak A. ; Heasley S. E. ; Kwon S. ; Langille J. ; Parikh M. D. ; Griffin S. H. ; Casavant J. M. ; Duclos B. A. ; Fenwick A. E. ; Harris T. M. ; Han S. ; Caspers N. ; Dowty M. E. ; Yang X. ; Banker M. E. ; Hegen M. ; Symanowicz P. T. ; Li L. ; Wang L. ; Lin T. H. ; Jussif J. ; Clark J. D. ; Telliez J.-B. ; Robinson R. P. ; Unwalla R. 
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
(PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment
of Autoimmune Diseases . J. Med. Chem. 
2018 , 61 , 1130 –1152 . 10.1021/acs.jmedchem.7b01598 .29298069 
a Chakka N. ; Bregman H. ; Du B. ; Nguyen H. N. ; Buchanan J. L. ; Feric E. ; Ligutti J. ; Liu D. ; McDermott J. S. ; Zou A. ; McDonough S. I. ; Dimauro E. F. 
Discovery and Hit-to-lead Optimization of Pyrrolopyrimidines
as Potent, State-dependent Na(v)1.7 Antagonists . Bioorg. Med. Chem. Lett. 
2012 , 22 , 2052 –2062 . 10.1016/j.bmcl.2012.01.015 .22318156  b Lee J.-H. ; Shin S. C. ; Seo S. H. ; Seo Y. H. ; Jeong N. ; Kim C.-W. ; Kim E. E. ; Keum G. 
Synthesis and in Vitro Antiproliferative Activity of C5-benzyl Substituted
2-amino-pyrrolo[2,3-d]pyrimidines as Potent Hsp90 Inhibitors . Bioorg. Med. Chem. Lett. 
2017 , 27 , 237 –241 . 10.1016/j.bmcl.2016.11.062 .27914802 
Perlíková P. ; Hocek M. 
Pyrrolo[2,3-d]pyrimidine
(7-deazapurine) as a Privileged Scaffold
in Design of Antitumor and Antiviral Nucleosides . Med. Res. Rev. 
2017 , 37 , 1429 –1460 . 10.1002/med.21465 .28834581 
a Bourderioux A. ; Nauš P. ; Perlíková P. ; Pohl R. ; Pichová I. ; Votruba I. ; Džubák P. ; Konečný P. ; Hajdúch M. ; Stray K. M. ; Wang T. ; Ray A. S. ; Feng J. Y. ; Birkus G. ; Cihlar T. ; Hocek M. 
Synthesis
and Significant
Cytostatic Activity of 7-hetaryl-7-deazaadenosines . J. Med. Chem. 
2011 , 54 , 5498 –5507 . 10.1021/jm2005173 .21711054  b Wu R. ; Smidansky E. D. ; Oh H. S. ; Takhampunya R. ; Padmanabhan R. ; Cameron C. E. ; Peterson B. R. 
Synthesis of a 6-Methyl-7-deaza Analogue
of Adenosine That Potently Inhibits Replication of Polio and Dengue
Viruses . J. Med. Chem. 
2010 , 53 , 7958 –7966 . 10.1021/jm100593s .20964406  c Nauš P. ; Caletková O. ; Konečný P. ; Džubák P. ; Bogdanová K. ; Kolář M. ; Vrbková J. ; Slavětínská L. ; Tloušt’ová E. ; Perlíková P. ; Hajdúch M. ; Hocek M. 
Synthesis, Cytostatic, Antimicrobial, and anti-HCV Activity of 6-substituted
7-(het)aryl-7-deazapurine Ribonucleosides . J.
Med. Chem. 
2014 , 57 , 1097 –1110 . 10.1021/jm4018948 .24397620 
a Tumkevicius S. ; Dodonova J. 
Functionalization of
Pyrrolo[2,3-d]pyrimidine by Palladium-catalyzed Cross-coupling
Reactions
(review) . Chem. Heterocycl. Compd. 
2012 , 48 , 258 –279 . 10.1007/s10593-012-0986-2 . b Krömer M. ; Klečka M. ; Slavětínská L. ; Klepetářová B. ; Hocek M. 
Chemoselective Synthesis
of 4,5-Diarylpyrrolo[2,3-d]pyrimidines (6,7-Diaryl-7-deazapurines)
by Consecutive Suzuki and Liebeskind-Srogl Cross-Couplings . Eur. J. Org. Chem. 
2014 , 7203 –7210 . 10.1002/ejoc.201402882 . c Dodonova J. ; Tumkevicius S. 
Fused Pyrrolo[2,3-d]pyrimidines (7-Deazapurines)
by Palladium-Catalyzed Direct N–H and C–H Arylation
Reactions . Synthesis 
2017 , 49 , 2523 –2534 . 10.1055/s-0036-1588734 . d Prieur V. ; Rubio-Martínez J. ; Font-Bardia M. ; Guillaumet G. ; Pujol M. D. 
Microwave-Assisted Synthesis of Substituted
Pyrrolo[2,3-d ]pyrimidines . Eur. J. Org. Chem. 
2014 , 1514 –1524 . 10.1002/ejoc.201301496 . e Tumkevicius S. ; Dodonova J. ; Kazlauskas K. ; Masevicius V. ; Skardziute L. ; Jursenas S. 
Synthesis and Photophysical
Properties of Oligoarylenes with a Pyrrolo[2,3-d]pyrimidine Core . Tetrahedron Lett. 
2010 , 51 , 3902 –3906 . 10.1016/j.tetlet.2010.05.093 . f Prieur V. ; Heindler N. ; Rubio-Martínez J. ; Guillaumet G. ; Pujol M. D. 
One-pot Synthesis of 4-aminated Pyrrolo[2,3-d]pyrimidines
from Alkynylpyrimidines Under Metal-catalyst-free Conditions . Tetrahedron 
2015 , 71 , 1207 –1214 . 10.1016/j.tet.2015.01.012 .
a Gayakhe V. ; Sanghvi Y. S. ; Fairlamb I. J. S. ; Kapdi A. R. 
Catalytic
C–H bond functionalisation of purine and pyrimidine nucleosides:
a synthetic and mechanistic perspective . Chem.
Commun. 
2015 , 51 , 11944 –11960 . 10.1039/c5cc03416g . b Liang Y. ; Wnuk S. 
Modification of Purine and Pyrimidine
Nucleosides by Direct C-H Bond Activation . Molecules 
2015 , 20 , 4874 –4901 . 10.3390/molecules20034874 .25789821  c Abdoli M. ; Mirjafary Z. ; Saeidian H. ; Kakanejadifard A. 
New Developments
in Direct Functionalization of C–H and N–H Bonds of
Purine Bases via Metal Catalyzed Cross-coupling Reactions . RSC Adv. 
2015 , 5 , 44371 –44389 . 10.1039/c5ra04406e .
a Klečka M. ; Pohl R. ; Klepetářová B. ; Hocek M. 
Direct C-H Borylation and C-H Arylation of Pyrrolo[2,3-d]pyrimidines:
Synthesis of 6,8-disubstituted 7-deazapurines . Org. Biomol. Chem. 
2009 , 7 , 866 –868 . 10.1039/b900218a .19225668  b Klečka M. ; Slavětínská L. P. ; Hocek M. 
Modification of Pyrrolo[2,3-d ]pyrimidines by C-H Borylation Followed
by Cross-Coupling or Other Transformations: Synthesis of 6,8-Disubstituted
7-Deazapurine Bases . Eur. J. Org. Chem. 
2015 , 7943 –7961 . 10.1002/ejoc.201501177 .
a Sabat N. ; Klečka M. ; Slavětínská L. ; Klepetářová B. ; Hocek M. 
Direct C-H Amination
and C-H Chloroamination of 7-deazapurines . RSC
Adv. 
2014 , 4 , 62140 –62143 . 10.1039/c4ra13143f . b Kavoosi S. ; Rayala R. ; Walsh B. ; Barrios M. ; Gonzalez W. G. ; Miksovska J. ; Mathivathanan L. ; Raptis R. G. ; Wnuk S. F. 
Synthesis of 8-(1,2,3-triazol-1-yl)-7-deazapurine
Nucleosides by Azide-alkyne Click Reactions and Direct C-H Bond Functionalization . Tetrahedron Lett. 
2016 , 57 , 4364 –4367 . 10.1016/j.tetlet.2016.08.053 .28239199 
Sabat N. ; Slavětínská L. P. ; Klepetářová B. ; Hocek M. 
C-H Phosphonation of Pyrrolopyrimidines: Synthesis of Substituted
7- and 9-Deazapurine-8-phosphonate Derivatives . J. Org. Chem. 
2016 , 81 , 9507 –9514 . 10.1021/acs.joc.6b01970 .27643727 
Klečka M. ; Pohl R. ; Čejka J. ; Hocek M. 
Direct C-H Sulfenylation
of Purines and Deazapurines . Org. Biomol. Chem. 
2013 , 11 , 5189 –5193 . 10.1039/c3ob40881g .23824343 
Sabat N. ; Slavětínská L. P. ; Hocek M. 
Ir-catalyzed C–H
Silylations of Phenyldeazapurines . Tetrahedron
Lett. 
2015 , 56 , 6860 –6862 . 10.1016/j.tetlet.2015.10.089 .
a Wang S. ; Ni Z. ; Huang X. ; Wang J. ; Pan Y. 
Copper-catalyzed Direct Amidation
of Heterocycles with N-fluorobenzenesulfonimide . Org. Lett. 
2014 , 16 , 5648 –5651 . 10.1021/ol502724u .25310043  b Kawakami T. ; Murakami K. ; Itami K. 
Catalytic C-H Imidation
of Aromatic Cores of Functional Molecules: Ligand-accelerated Cu Catalysis
and Application to Materials- and Biology-oriented Aromatics . J. Am. Chem. Soc. 
2015 , 137 , 2460 –2463 . 10.1021/ja5130012 .25669319 
Boursalian G. B. ; Ngai M.-Y. ; Hojczyk K. N. ; Ritter T. 
Pd-catalyzed Aryl C-H
Imidation with Arene as the Limiting Reagent . J. Am. Chem. Soc. 
2013 , 135 , 13278 –13281 . 10.1021/ja4064926 .23998528 
Song L. ; Zhang L. ; Luo S. ; Cheng J.-P. 
Visible-light Promoted
Catalyst-free Imidation of Arenes and Heteroarenes . Chem.—Eur. J. 
2014 , 20 , 14231 –14234 . 10.1002/chem.201404479 .25212493 
Kim H. ; Kim T. ; Lee D. G. ; Roh S. W. ; Lee C. 
Nitrogen-centered Radical-mediated
C-H Imidation of Arenes and Heteroarenes via Visible Light Induced
Photocatalysis . Chem. Commun. 
2014 , 50 , 9273 –9276 . 10.1039/c4cc03905j .
Foo K. ; Sella E. ; Thomé I. ; Eastgate M. D. ; Baran P. S. 
A Mild,
Ferrocene-catalyzed C-H Imidation of (hetero)arenes . J. Am. Chem. Soc. 
2014 , 136 , 5279 –5282 . 10.1021/ja501879c .24654983 
Farrugia L.
J. 
WinGX and
ORTEP for Windows: an update . J. Appl. Crystallogr. 
2012 , 45 , 849 –854 . 10.1107/s0021889812029111 .
a Diana P. ; Barraja P. ; Lauria A. ; Almerico A. M. ; Dattolo G. ; Cirrincione G. 
Protonation
of aminoindoles . Tetrahedron 
2000 , 56 , 5177 –5183 . 10.1016/s0040-4020(00)00180-0 . b Hino T. ; Nakagawa M. ; Hashizume T. ; Yamaji N. ; Miwa Y. 
Autoxidation of 2-aminoindoles to
3-oxo-derivatives . Tetrahedron Lett. 
1970 , 11 , 2205 –2208 . 10.1016/s0040-4039(01)98190-0 .

